NCT06532006
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06532006
Title A Phase III Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Shanghai Henlius Biotech
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS


No variant requirements are available.